World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
33761
World Ranking
15901
National Ranking
8002

Overview

Kenneth C. Kalunian is affiliated with the University of California, San Diego in the United States and has made significant contributions to medical research, particularly in the field of rheumatology. Their work primarily focuses on systemic lupus erythematosus (SLE), monoclonal and polyclonal antibodies, and related autoimmune conditions.

Kalunian's research encompasses a broad spectrum of topics within medicine, with a strong emphasis on:

  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Atherosclerosis and Cardiovascular Diseases
  • Liver Diseases and Immunity
  • Renal Diseases and Glomerulopathies
  • Rheumatoid Arthritis Research and Therapies
  • T-cell and B-cell Immunology

Their scientific output falls predominantly within the main field of Medicine and more specifically within subfields such as Rheumatology, Immunology, Radiology, Nuclear Medicine and Imaging, Genetics, and Pathology and Forensic Medicine. Their research articles have appeared in several leading journals and publication venues, including:

  • Annals of the Rheumatic Diseases
  • Lupus Science & Medicine
  • UNC Libraries
  • Arthritis Care & Research
  • The Journal of Rheumatology

Recent publications by Kenneth C. Kalunian illustrate their focus on clinical trials and therapeutic interventions for lupus and related autoimmune diseases. Selected recent papers include:

  • "Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)" (2023, The Lancet)
  • "A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus" (2022, Arthritis & Rheumatology)
  • "Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials" (2022, Annals of the Rheumatic Diseases)
  • "Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus" (2022, New England Journal of Medicine)
  • "Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus" (2022, New England Journal of Medicine)

Collaboration is a notable aspect of Kalunian's research career, counting frequent co-authors such as Diane L. Kamen, Michelle Petri, Daniel J. Wallace, Anca Askanase, and Ian N Bruce. These collaborative relationships further reflect the extensive engagement in the field of lupus and autoimmune disorders.

Best Publications

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

    Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon

  • The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

    Dafna Gladman;Ellen Ginzler;Charles Goldsmith;Paul Fortin

  • Combined oral contraceptives in women with systemic lupus erythematosus

    Michelle Petri;Mimi Y. Kim;Kenneth C. Kalunian;Jennifer Grossman

  • Anifrolumab, an Anti–Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

    Richard Furie;Munther Khamashta;Joan T. Merrill;Victoria P. Werth

  • The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.

    Dafna D. Gladman;Murray B. Urowitz;Charles H. Goldsmith;Paul Fortin

  • The immune cell landscape in kidneys of patients with lupus nephritis

    Arnon Arazi;Deepak A Rao;Celine C Berthier;Anne Davidson

  • The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial

    Jill P. Buyon;Michelle A. Petri;Mimi Y. Kim;Kenneth C. Kalunian

  • A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.

    Gary S. Hoffman;Maria C. Cid;David B. Hellmann;Loic Guillevin

  • The frequency and outcome of lupus nephritis: results from an international inception cohort study

    John G. Hanly;Aidan G. O'Keeffe;Li Su;Murray B. Urowitz

  • Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Ian N Bruce;Aidan G O'Keeffe;Vernon Farewell;John G Hanly

  • Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

    Daniel J Wallace;Richard A Furie;Yoshiya Tanaka;Kenneth C Kalunian

  • Proinflammatory high‐density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis

    Maureen McMahon;Jennifer Grossman;John FitzGerald;Erika Dahlin-Lee

  • Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

    Munther Khamashta;Joan T Merrill;Victoria P Werth;Victoria P Werth;Richard Furie

  • Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

    Kenneth C. Kalunian;John C. Davis;Joan T. Merrill;Mark C. Totoritis

  • Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

    Richard A Furie;Eric F Morand;Ian N Bruce;Susan Manzi

  • Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.

    Daniel J Wallace;Kenneth Kalunian;Michelle A Petri;Vibeke Strand

  • Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

    Maria Dall'Era;Eliza Chakravarty;Daniel Wallace;Mark Genovese

  • A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

    Kenneth C Kalunian;Joan T Merrill;Romeo Maciuca;Jacqueline M McBride

  • Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study

    J. G. Hanly;M. B. Urowitz;J. Sanchez-Guerrero;S. C. Bae

  • Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus.

    B P Tsao;R M Cantor;K C Kalunian;C J Chen

Frequent Co-Authors

Joan T. Merrill
Joan T. Merrill Oklahoma Medical Research Foundation
Daniel J. Wallace
Daniel J. Wallace Cedars-Sinai Medical Center
Michelle Petri
Michelle Petri Johns Hopkins University School of Medicine
Caroline Gordon
Caroline Gordon University of Birmingham
Ian N. Bruce
Ian N. Bruce University of Manchester
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Murray B. Urowitz
Murray B. Urowitz University of Toronto
Paul R. Fortin
Paul R. Fortin Université Laval
David A. Isenberg
David A. Isenberg University College London
Susan Manzi
Susan Manzi Allegheny Health Network

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in healthcare doesn’t always mean pursuing a traditional path to becoming a physician. There are multiple online degree options and career routes available for those interested in working in the healthcare sector.

For professionals with a non-nursing bachelor’s degree looking to break into nursing, non nursing bachelor's to msn online programs offer a fast track to earning an advanced degree and entering the field. If you’re concerned about entrance exams, there are also nursing school without teas test requirements, making the application process more accessible.

Some prospective students seek what is the easiest nursing program to get into to help launch their careers more quickly or with fewer hurdles. For those interested in roles related to healthcare administration, exploring accredited medical billing and coding schools online with financial aid can open doors to a stable, in-demand field.

Whether you’re aiming for a patient-facing or administrative role, many online options make it easier to begin a healthcare career on your terms.

Best Scientists Citing Kenneth C. Kalunian

Trending Scientists

Recently Published Articles